

WOAH Reference Laboratory Reports Activities 2025

This report has been submitted: 29 janvier 2026 08:48

LABORATORY INFORMATION

*Name of disease (or topic) for which you are a designated WOA Reference Laboratory:	Avian chlamydiosis
*Address of laboratory:	
*Tel:	+330149771350
*E-mail address:	karine.laroucau@anses.fr
Website:	
*Name (including Title) of Head of Laboratory (Responsible Official):	Dr Zientara Stéphan
*Name (including Title and Position) of WOA Reference Expert:	Dr Laroucau Karine
*Which of the following defines your laboratory? Check all that apply:	Governmental

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOA Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests			
Direct diagnostic tests			
real-time PCR Chlamydiaceae	Yes	2450	195
real-time PCR C. psittaci	Yes	2078	3
real-time PCR C. abortus	Yes	16	3
real-time PCR C. gallinacea	Yes	16	3
real-time PCR C. avium	Yes	18	3
MLST C. psittaci	Yes	4	0

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOA Members?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient WOA Member Countries	Country of recipients
DNA of Chlamydia ref	real-time PCR	produced	10 * 100 µL	0	6	FRANCE,

Karine Laroucau - - FRANCE

strains

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOAHA Members?

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOAHA Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

9. Did your laboratory validate vaccines according to WOAHA Standards for the designated pathogen or disease?

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOAHA Members?

No

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAHA Member?

Yes

Name of the WOAHA Member Country receiving a technical consultancy	Purpose	How the advice was provided
ARGENTINA	SOP for <i>C. psittaci</i> and avian strains of <i>C. abortus</i>	remote assistance by email
SPAIN	information about CFT reagents	remote assistance by email
ITALY	Avian chlamydiosis epidemiology	remote assistance by email

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOAHA Members other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	WOAHA Member Countries involved other than your country
Prevalence of Chlamydiaceae in wild birds	2 years	To study the prevalence and strain diversity of Chlamydiaceae in birds	University of Sao Paulo	BRAZIL

13. In exercising your activities, have you identified any regulatory research needs* relevant for WOAHA?

No

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

8

Borel N, Longbottom D, Greub G, Albini S, Vanrompay D, Laroucau K. Zoonotic infections due to avian *Chlamydia abortus*: what are we missing? *Lancet Microbe*. 2025

Karine Laroucau - - FRANCE

Nov;6(11):101197. doi: 10.1016/j.lanmic.2025.101197. Epub 2025 Aug 20. PMID: 40848734

Ornelas-Eusebio E, Vorimore F, Aaziz R, Mandola ML, Rizzo F, Marchino M, Nogarol C, Risco-Castillo V, Zanella G, Schnee C, Sachse K, Laroucau K. *Trichosporon asahii*: A Potential Growth Promoter for *C. gallinacea*? Implications for Chlamydial Infections and Cell Culture. *Microorganisms*. 2025 Jan 27;13(2):288. doi: 10.3390/microorganisms13020288. PMID: 40005655

Bralet T, Aaziz R, Tomos J, Gamble A, Clessin A, Lejeune M, Galon C, Michelet L, Lesage C, Jeanniard du Dot T, Desoubieux G, Guyard M, Delannoy S, Moutailler S, Laroucau K, Boulinier T. High-throughput microfluidic real-time PCR as a promising tool in disease ecology. *J Anim Ecol*. 2025 Sep;94(9):1625-1637. doi: 10.1111/1365-2656.70088. Epub 2025 Jun 27. PMID: 40576224

Schnee C, Laroucau K, Livingstone M, Aaziz R, Marti H, Longbottom D, Borel N. Cross-European laboratory evaluation of commercial and in-house real-time PCR assays for the detection of *Chlamydia abortus* in small ruminants. *Res Vet Sci*. 2025 Jun;188:105613. doi: 10.1016/j.rvsc.2025.105613. Epub 2025 Mar 15. PMID: 40120389

Hölzer M, Reuschel C, Vorimore F, Laroucau K, Sachse K. Exploring the genomic landscape of *Chlamydia* species: novel features include multiple truncated major outer membrane proteins, unique genes and chlamydial plasticity zone orthologs. *Access Microbiol*. 2025 Feb 3;7(2):000936.v3. doi: 10.1099/acmi.0.000936.v3. eCollection 2025. PMID: 40697354

Le Gall-Ladevèze C, Vollet B, Hirschinger J, Lèbre L, Aaziz R, Laroucau K, Guérin JL, Paul M, Cappelle J, Le Loc'h G. Limited transmission of avian influenza viruses, avulaviruses, coronaviruses and *Chlamydia* sp. at the interface between wild birds and a free-range duck farm. *Vet Res*. 2025 Feb 8;56(1):36. doi: 10.1186/s13567-025-01466-3. PMID: 39923111

Lawson JM, Verheyen KL, Laroucau K, Bryan JS, Smith KC, Foote AK, de Mestre AM. Umbilical cord torsion abortion: the gross and histological features of affected umbilical cords and fetal membranes. *Theriogenology*. 2026 Mar 1;252:117771. doi: 10.1016/j.theriogenology.2025.117771. Epub 2025 Nov 21. PMID: 41338002

Monireh Khordadmehr, Faeghehossadat Mousavi, Katayoon Nofouzi, Karine Laroucau, Farinaz Jigari Asl, Moein Zehtab Najafi, Seyed Hossein Jarolmasjed *Histopathological and Molecular Investigation of Chlamydia felis* Infection in Cat Uterus Underwent Ovariohysterectomy Surgery. 2025. *Iranian Journal of Veterinary Surgery*

b) International conferences:

1

Laroucau K. *ChlamHealth - zoonotic chlamydial infections: What's new? Part 1: birds. ESGMAC (ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC)) - Zoonotic and veterinary chlamydiae. December 10 2025.*

c) National conferences:

1

Bralet T, Boulinier T, Laroucau K. *Hétérogénéité des communautés d'agents infectieux des populations d'oiseaux marins des îles subantarctiques CNFRAA (21èmes Journées Scientifiques du CNFRAA - CNFRAA) Grenoble*

d) Other (Provide website address or link to appropriate information):

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOA Members?

Yes

a) Technical visit : 0

b) Seminars : 0

c) Hands-on training courses: 0

d) Internships (>1 month) 1

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
D	BRAZIL	1

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO17025	PDF	Attestation 1-7341_Rév02.pdf

Karine Laroucau - - FRANCE

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
real-time PCR Chlamydiaceae	COFRAC

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

Regular risk assessments for Chlamydia agents are carried out and updated as needed. Biosafety and biosecurity measures are implemented under the supervision of a biological risk manager, and the BSL-3 laboratory is routinely inspected by national authorities to ensure regulatory compliance.

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOAHP?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOAHP?

No

TOR10: NETWORK WITH WOAHP REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOAHP Reference Laboratories designated for the same pathogen or disease?

Yes

24. Are you a member of a network of WOAHP Reference Laboratories designated for the same pathogen?

Yes

NETWORK/DISEASE	ROLE OF YOUR LABORATORY (PARTICIPANT, ORGANISER, ETC)	NO. PARTICIPANTS	PARTICIPATING WOAHP REF. LABS
Avian chlamydiosis	participant	2	WOAHP ref lab from Germany (FLI) and France (Anses)

25. Did you organise or participate in inter-laboratory proficiency tests with WOAHP Reference Laboratories designated for the same pathogen during the past 2 years?

Yes

Purpose of the proficiency test:	Role of your Reference Laboratory (organiser/ participant)	No. participating Laboratories	Participating WOAHP Ref. Labs/ organising WOAHP Ref Lab
Assessment of technical competence of laboratories in detection of Chlamydiaceae, Chlamydia psittaci, and other avian species genomic DNA in different matrices by real-time PCR	participant	2 WOAHP ref labs	WOAHP ref lab from Germany (FLI) and France (Anses)

26. Did your laboratory collaborate with other WOAHP Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAHP Reference Laboratories for the same pathogen during the past 2 years?

Yes

Purpose for inter-laboratory test comparisons ¹	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Name of the test	WOAHP Member Countries
real-time PCR results comparison	Participant	2	PCR	CROATIA,

Karine Laroucau - - FRANCE

Assessment of technical competence of laboratories in detection of *Chlamydia psittaci* genomic DNA in different matrices by real-time PCR

Participant

33

LVU Chlamydien 2024

AUSTRIA, BELGIUM, FRANCE,
GERMANY, POLAND,
SWITZERLAND,

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOAHP?

No

29. Additional comments regarding your report:

No